Browse studies

Find your next paid study

41 recruiting studies matching your filters

Life on the Go 3: A Randomized Controlled Trial of Automated, Personalized Physical Activity Intervention Using Wearable Devices to Improve Immune Function and Clinical Outcomes in Ovarian and Endometrial Cancer Patients

This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on phy…

Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+10 more

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT06855706

Phase 2

A Prospective Randomized Trial of Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer

Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a s…

Ovarian CancerFallopian Tube CarcinomaOvarian Carcinoma+7 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06290193

Phase 2

Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Epithelial Ovarian CancerPrimary PeritonealFallopian Tube Cancer+1 more

Estimated

~$10 – $8,750

TORL Biotherapeutics, LLCNCT06690775

Phase 1

A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynami…

Solid TumorEpithelial Ovarian CancerFallopian Tube Cancer+1 more

Estimated

~$10 – $8,750

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04516447

Phase 2

A Phase 2 Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with cle…

Ovary CancerFallopian Tube CancerPrimary Peritoneal Cavity Cancer

Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06617923